Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO). Phase I.

The article discusses a newly launched clinical trial, NCT06503848, which aims to identify differential traits in spontaneous migraine attacks that can help predict the response to treatment with sumatriptan. Participants in the study will be asked to register the characteristics of their headaches before and after taking sumatriptan, and whether the treatment was effective or not during four migraine attacks. The study seeks to determine which characteristics are associated with a response or non-response to acute treatment with sumatriptan, in order to offer personalized treatment options. The trial is currently recruiting participants in Spain. [Extracted from the article]